Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14779149 | 0.98 | LMNA (0.39) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| Bromide SCHEMBL14779567 | 0.98 | LMNA (0.39) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| Iodide SCHEMBL14778058 | 0.98 | LMNA (0.39) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| SCHEMBL22500701 | 0.98 | SMN1; SMN2 (0.39) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| SCHEMBL22500789 | 0.98 | LMNA (0.42) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| SCHEMBL3814229 | 0.96 | SMN1; SMN2 (0.40) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| SCHEMBL22501068 | 0.92 | LMNA (0.46) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| SCHEMBL22500693 | 0.92 | ALDH1A1 (0.36) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| SCHEMBL3812431 | 0.90 | ALDH1A1 (0.38) | LMNAALDH1A1KMT2AHSD17B10MEN1 | |
| SCHEMBL3813544 | 0.88 | SMN1; SMN2 (0.46) | LMNAALDH1A1KMT2AHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108600-A1 | METHODS AND COMPOSITIONS RELATING TO IMPROVED IONIC LIQUID ADJUVANTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250041239-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | ISHA Therapeutics LLC (US) | 2025-02-06 | — | — | US | disclosed |
| US-12109303-B2 | Orally dissolving antimicrobial film compositions and methods of their use | ISHA Therapeutics LLC (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2024076715-A1 | METHODS AND COMPOSITIONS RELATING TO IMPROVED IONIC LIQUID ADJUVANTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240016735-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023205615-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | ISHA Therapeutics LLC (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230330012-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | ISHA Therapeutics LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230310350-A1 | ANTIFUNGAL PROPHYLAXIS FOR CORNEA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-05 | — | — | US | disclosed |
| US-11684594-B2 | Antifungal prophylaxis for cornea | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-27 | — | — | US | disclosed |
| CN-115996751-A | Methods and compositions relating to ionic liquid adjuvants | 哈佛大学校长及研究员协会 | 2023-04-21 | — | — | CN | disclosed |
| US-20230102247-A1 | METHODS AND COMPOSITIONS RELATING TO IONIC LIQUID ADJUVANTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2022256291-A1 | HYDROGEL DEVICES FOR DRUG DELIVERY TO THE EAR | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-4061338-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-114980864-A | Ionic liquids for drug delivery | 哈佛大学校长及研究员协会 | 2022-08-30 | — | — | CN | disclosed |
| US-20220257767-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3946261-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | President And Fellows Of Harvard College (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939273-A | Ionic liquids for drug delivery | 哈佛大学校长及研究员协会 | 2022-01-14 | — | — | CN | disclosed |
| US-20210353565-A1 | ANTIFUNGAL PROPHYLAXIS FOR CORNEA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-18 | — | — | US | disclosed |
| WO-2020205409-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016735-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | LMNA 725/4885ALDH1A1 898/4885KMT2A 3722/4885 |
| US-20260108600-A1 | METHODS AND COMPOSITIONS RELATING TO IMPROVED IONIC LIQUID ADJUVANTS | ICOS, ICOSLG, TLR9 | LMNA 3035/4885ALDH1A1 4423/4885KMT2A 1531/4885 |
| US-20210353565-A1 | ANTIFUNGAL PROPHYLAXIS FOR CORNEA | ERG28, DPM1, CHI3L1 | LMNA 2722/4885ALDH1A1 3413/4885KMT2A 3766/4885 |
| US-20230310350-A1 | ANTIFUNGAL PROPHYLAXIS FOR CORNEA | ERG28, DPM1, CHI3L1 | LMNA 2722/4885ALDH1A1 3413/4885KMT2A 3766/4885 |
| US-20250041239-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | RAB5IF, CGAS, APOB | LMNA 3264/4885ALDH1A1 2777/4885KMT2A 4819/4885 |
| US-20230330012-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | RAB5IF, CGAS, APOB | LMNA 3264/4885ALDH1A1 2777/4885KMT2A 4819/4885 |
| US-20220257767-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | LMNA 725/4885ALDH1A1 898/4885KMT2A 3722/4885 |
| US-11684594-B2 | Antifungal prophylaxis for cornea | ERG28, DPM1, CHI3L1 | LMNA 2722/4885ALDH1A1 3413/4885KMT2A 3766/4885 |
| US-20230102247-A1 | METHODS AND COMPOSITIONS RELATING TO IONIC LIQUID ADJUVANTS | MYD88, TLR7, TLR9 | LMNA 1658/4885ALDH1A1 4776/4885KMT2A 3953/4885 |
| US-12109303-B2 | Orally dissolving antimicrobial film compositions and methods of their use | RAB5IF, APOB, ERG28 | LMNA 3506/4885ALDH1A1 3284/4885KMT2A 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.